Communication materials on the safety of the use of the medicinal product ALTIOZA (thiocolchicoside). Minimizing the risk of aneuploidy (genotoxicity/embryotoxicity).

03.07.2026 232 views

Інформаційний-лист звернення до спеціалістів системи охорони здоров’я та картку пацієнта щодо безпеки застосування лікарського засобу АЛЬТІОЗАPDF · 573 КБ

Завантажити

Картка пацієнтаPDF · 342 КБ

Завантажити

Communication materials on the safety of the use of the medicinal product ALTIOZA (thiocolchicoside). Minimizing the risk of aneuploidy (genotoxicity/embryotoxicity).

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Communication materials on the safety of the use of the medicinal product ALTIOZA (thiocolchicoside). Minimizing the risk of aneuploidy (genotoxicity/embryotoxicity).

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration